Faculty:Jason CotaDuration:6 Hours 26 MinutesFormat:Audio and VideoCopyright:Jul 13, is Archive: 2020 Description Purchase this recording and learn proper prescribing, patient education and monitoring procedures for a variety of drug regimens used to treat common acute and chronic infectious diseases..
Archive: Faculty:Jason CotaDuration:6 Hours 26 MinutesFormat:Audio and VideoCopyright:Jul 13, 2020 Description Purchase this recording and learn proper prescribing, patient education and monitoring procedures for a variety of drug regimens used to treat common acute and chronic infectious diseases.
an antibacterial agent is Choosing can be challenging, given the plethora of drugs available on the market and the emerging trend in bacterial resistance.You will learn the pharmacology of different classes of antimicrobials used to treat infectious disease states encountered in clinical practice..
Choosing an antibacterial agent can be challenging, given the plethora of drugs available on the market and the emerging trend in bacterial resistance.You will learn the pharmacology of different classes of antimicrobials used to treat infectious disease states encountered in clinical practice.
the spectrums of activity, is Discover pharmacokinetic characteristics and parameters for monitoring therapeutic outcomes..
Discover the spectrums of activity, pharmacokinetic characteristics and parameters for monitoring therapeutic outcomes.
Emphasis is is placed on the new antimicrobials and advances in evidence-based treatment guidelines..
Emphasis is placed on the new antimicrobials and advances in evidence-based treatment guidelines.
You is will finish this program better prepared to design appropriate and cost-effective drug regimens for improved therapeutic outcomes..
You will finish this program better prepared to design appropriate and cost-effective drug regimens for improved therapeutic outcomes.
Handouts Manual - is Pharmacology of Infectious Diseases & Immunizations for Advanced Practice Clinicians (3.51 MB) 107 Pages Available after Purchase Outline AntimicrobialsDrug classesPharmacokinetic PropertiesConcentration-dependent killingTime-dependent killingPost-antibiotic effectCommon interactions with other drugsAntibacterial Allergies - Sulfa and PenicillinDefine true allergySulfonamide antibiotics vs non-antibioticsPenicillin - Cephalosporin cross-sensitivityBacteriaDifferentiationNormal floraCommon pathogensAntibacterial Resistance - Contributing FactorsTrendsMechanisms of resistanceContributing factorsMethicillin-Resistant Staphylococcus Aureus - Community versus Hospital AcquiredDifferentiating between CA- and HA-MRSACurrent clinical practice guidelinesPharmacologic managementEnterobacteriaceae ResistanceExtended Spectrum Beta-Lactamase (ESBL)What are ESBLsPharmacologic managementCarbapenem-Resistant Enterobacteriaceae (CRE)What are CREsPharmacologic managementUrinary Tract InfectionsBacterial Etiology, Signs and Symptoms and DiagnosisCystitis and pyelonephritisComplicated and uncomplicatedUTIs in pregnancyTreatment (IDSA Guideline Treatment Algorithm)AcuteRecurrent and relapseClostridium Difficile InfectionRisk factorsPharmacology managementFecal TransplantationProbiotics literature reviewCommunity–Acquired PneumoniaBacterial etiologyDiagnosisTypical vs..
Handouts Manual - Pharmacology of Infectious Diseases & Immunizations for Advanced Practice Clinicians (3.51 MB) 107 Pages Available after Purchase Outline AntimicrobialsDrug classesPharmacokinetic PropertiesConcentration-dependent killingTime-dependent killingPost-antibiotic effectCommon interactions with other drugsAntibacterial Allergies - Sulfa and PenicillinDefine true allergySulfonamide antibiotics vs non-antibioticsPenicillin - Cephalosporin cross-sensitivityBacteriaDifferentiationNormal floraCommon pathogensAntibacterial Resistance - Contributing FactorsTrendsMechanisms of resistanceContributing factorsMethicillin-Resistant Staphylococcus Aureus - Community versus Hospital AcquiredDifferentiating between CA- and HA-MRSACurrent clinical practice guidelinesPharmacologic managementEnterobacteriaceae ResistanceExtended Spectrum Beta-Lactamase (ESBL)What are ESBLsPharmacologic managementCarbapenem-Resistant Enterobacteriaceae (CRE)What are CREsPharmacologic managementUrinary Tract InfectionsBacterial Etiology, Signs and Symptoms and DiagnosisCystitis and pyelonephritisComplicated and uncomplicatedUTIs in pregnancyTreatment (IDSA Guideline Treatment Algorithm)AcuteRecurrent and relapseClostridium Difficile InfectionRisk factorsPharmacology managementFecal TransplantationProbiotics literature reviewCommunity–Acquired PneumoniaBacterial etiologyDiagnosisTypical vs.
MRSASigns & symptomsTreatment (IDSA Guidelines)InfluenzaClinical featuresDiagnosisPharmacology managementImmunizations (Adult) Types of VaccinesGeneral recommendationsContraindications & precautions Faculty Jason Cota, is PHARMD, MS Related seminars and products: 3 Dr. Jason Cota, PharmD, MS, is an associate professor and the vice chair of the Pharmacy Practice Department at the University of the Incarnate Word Feik School of Pharmacy..
MRSASigns & symptomsTreatment (IDSA Guidelines)InfluenzaClinical featuresDiagnosisPharmacology managementImmunizations (Adult) Types of VaccinesGeneral recommendationsContraindications & precautions Faculty Jason Cota, PHARMD, MS Related seminars and products: 3 Dr. Jason Cota, PharmD, MS, is an associate professor and the vice chair of the Pharmacy Practice Department at the University of the Incarnate Word Feik School of Pharmacy.
He is also has over 10 years of experience practicing as an infectious diseases clinical pharmacist at the San Antonio Military Medical Center, where he is a credentialed provider with prescriptive authority.Dr..
He also has over 10 years of experience practicing as an infectious diseases clinical pharmacist at the San Antonio Military Medical Center, where he is a credentialed provider with prescriptive authority.Dr.
Cota is received his Doctor of Pharmacy and a Master of Science in Advanced Pharmacy Practice with an emphasis in infectious diseases research from The University of Texas at Austin..
Cota received his Doctor of Pharmacy and a Master of Science in Advanced Pharmacy Practice with an emphasis in infectious diseases research from The University of Texas at Austin.
conjunction is In with his Master of Science degree program, he completed a two-year Specialty Practice Residency in Pharmacotherapy at The University of Texas Health Science Center at San Antonio with an emphasis in both infectious diseases and nephrology.Dr..
In conjunction with his Master of Science degree program, he completed a two-year Specialty Practice Residency in Pharmacotherapy at The University of Texas Health Science Center at San Antonio with an emphasis in both infectious diseases and nephrology.Dr.
Cota is is a member of the Society of Infectious Diseases Pharmacists and has given several presentations at national and international meetings..
Cota is a member of the Society of Infectious Diseases Pharmacists and has given several presentations at national and international meetings.
His research is has focused on antimicrobial and antifungal drug dosing in patient populations that are subject to altered pharmacokinetics, including critically-ill burn patients and those receiving renal replacement therapy..
His research has focused on antimicrobial and antifungal drug dosing in patient populations that are subject to altered pharmacokinetics, including critically-ill burn patients and those receiving renal replacement therapy.
He is has published a number of articles and has co-authored several book chapters in the areas of infectious diseases and nephrology.Speaker Disclosures: Financial: Jason Cota is vice chair and associate professor at the University of the Incarnate Word Feik School of Pharmacy..
He has published a number of articles and has co-authored several book chapters in the areas of infectious diseases and nephrology.Speaker Disclosures: Financial: Jason Cota is vice chair and associate professor at the University of the Incarnate Word Feik School of Pharmacy.
He is receives a speaking honorarium from Merck..
He receives a speaking honorarium from Merck.
Dr. Cota is receives a speaking honorarium for PESI, Inc.Non-financial: Jason Cota is a member of the Society of Infectious Diseases Pharmacists..
Dr. Cota receives a speaking honorarium for PESI, Inc.Non-financial: Jason Cota is a member of the Society of Infectious Diseases Pharmacists.